TheraCell delivers more than 25,000 licensed bone fibre grafts
TheraCell, a developer of technologies for bone and soft tissue repair, has announced that more than 25,000 of its demineralised bone fibre products have been delivered by its licensee partners, with annual end-customer sales approaching US$30m.
TheraCell has licensed the TheraFuze DBF technology to AlloSource to produce and market AlloFuse Cortical Fibers and AlloFuse Fiber Boats, and to produce private-label products to be marketed by other orthopaedic companies.
The technology has also been licensed to Australian Biotechnologies to produce and market AlloVance Xpress Fibres, AlloVance Xpress Hybrid, AlloVance Fibre Mats and AlloVance Fibre Boats for the Australian and New Zealand markets.
For the full story, see the January 2021 edition of Medical Textiles.